Targeted therapy for advanced Basal-cell carcinoma: vismodegib and beyond

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Basal-cell carcinoma (BCC) is a frequent skin cancer with potential for local invasion and distant spread.
• The Hedgehog signaling pathway is crucial in BCC pathogenesis and represents a viable therapeutic target.
• Recent molecular insights have driven the development of targeted therapies for advanced BCC.

Purpose of the Study:

• To review the clinical development and application of vismodegib, an FDA-approved Hedgehog pathway inhibitor for advanced BCC.
• To discuss the role of vismodegib in clinical practice and emerging challenges.
• To explore resistance mechanisms and other Hedgehog pathway inhibitors in development.

Main Methods:

• Review of clinical trial data and literature on vismodegib.
• Analysis of the Hedgehog pathway's role in basal-cell carcinoma.
• Discussion of current and future therapeutic strategies for advanced BCC.

Main Results:

• Vismodegib has demonstrated clinical activity and tolerability in patients with advanced BCC.
• FDA approval signifies a significant advancement in BCC treatment.
• Understanding resistance mechanisms is critical for optimizing therapy.

Conclusions:

• Vismodegib represents a targeted therapy breakthrough for advanced basal-cell carcinoma.
• Proper clinical application and management of resistance are key to successful treatment.
• Ongoing research into other Hedgehog pathway inhibitors holds promise for future BCC management.